多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌

Docetaxel combined with intraperitoneal hypothermic perfusion chemotherapy plus hyperthermia in the treatment of advanced ovarian cancer

目的探讨多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌患者的临床疗效。方法选取2011年1月至2012年12月收治的80例晚期卵巢癌患者为研究对象,依据随机数字法分为试验组和对照组。对照组给予多西他赛联合腹腔热灌注化疗,试验组在对照组的治疗基础上给予热疗,观察两组患者的临床疗效和不良反应。结果试验组总有效率(82.5%)显著高于对照组总有效率(60.0%),两组差异有统计学意义(P<0.05)。试验组白细胞减少、恶心与呕吐、消化道反应、肝功能损害的发生率均低于对照组,差异均有统计学意义(均P<0.05)。结论应用多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌可提高临床疗效,不良反应少,治疗安全性高,值得临床应用。

Objective To investigate the clinical efficacy of docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy plus hyperthermia therapy on advanced ovarian cancer patients. Methods Eighty cases with advanced ovarian cancer treated in our hospital from JAN 2011 to DEC 2012 were divided into observation group and control group by random numbers. The control group were treated with docetaxel combined with intraperitoneal hyperthermia perfusion chemotherapy, and the observation group were treated with docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy plus hyperthermia therapy. The clinical efficacy and toxicity of two group were observed. Results The overall response rate of the observation group was 82. 5%, which was significantly higher than that of control group （ P 〈 0. 05 ）. The incidences of leucopenia, nausea and vomiting, gastrointestinal reactions, liver dysfunc- tion in observation group were significantly lower than those of the control group （ P 〈 0. 05 ）. Conclusion The clinical application of docetaxel combined with intraperitoneal hyperthermia perfusion chemotherapy plus hyperthermia can elevate the overall response rate, reduce the adverse reaction rate, and be of safty ; thus, it is worthy of clinical application.